8-K: NRx Pharmaceuticals Announces 1-for-10 Reverse Stock Split to Maintain Nasdaq Listing

NRx Pharmaceuticals has announced a 1-for-10 reverse stock split of its common stock, effective April 1, 2024, to maintain its Nasdaq listing and attract institutional investors.

Summary

• NRx Pharmaceuticals has implemented a 1-for-10 reverse stock split of its common stock.
• The reverse stock split will be effective on April 1, 2024, at 4:30 PM Eastern Time.
• The number of outstanding shares will decrease from approximately 95.7 million to 9.6 million, subject to rounding up of fractional shares.
• The company's common stock will begin trading on a split-adjusted basis on April 2, 2024, on the Nasdaq Capital Market under the symbol NRXP.
• The reverse stock split is intended to increase the share price to meet institutional investor requirements and avoid penny stock rules.
• The company believes this action will create long-term shareholder value, especially with upcoming clinical trial data and a planned dividend of HOPE Therapeutics shares.

Sentiment

Score: 6

Explanation: The document is neutral to slightly positive. While the reverse stock split is a necessary action to maintain listing, the company is also highlighting potential positive catalysts such as clinical trial data and a planned dividend.

Positives

• The reverse stock split is expected to make the company more attractive to institutional investors.
• The company anticipates positive data readouts from clinical trials in the near term.
• A planned dividend of shares in HOPE Therapeutics could benefit existing shareholders.
• The expected filing of an NDA for ketamine in the second quarter is a positive development.

Negatives

• The reverse stock split will reduce the number of shares held by existing shareholders.
• The reverse stock split was necessary to maintain Nasdaq compliance, indicating potential past issues with share price.

Risks

• The company's future success depends on the outcome of clinical trials.
• There is no guarantee that the reverse stock split will achieve the desired effect of attracting institutional investors.
• The company's forward-looking statements are subject to risks and uncertainties.

Future Outlook

The company anticipates positive data from clinical trials in Suicidal Bipolar Depression and Chronic Pain, a planned dividend of shares in HOPE Therapeutics, and the expected filing of an NDA for ketamine in the second quarter. They also mention the potential for a forward stock split in the future if positive data is released.

Management Comments

• Dr. Jonathan Javitt, Founder, Chairman and Chief Scientist of NRx Pharmaceuticals, stated that the reverse stock split is consistent with creating long-term shareholder value.
• Dr. Javitt also mentioned that the company is well positioned to be attractive to many larger investors due to upcoming clinical trial data and the planned dividend of HOPE Therapeutics shares.

Industry Context

Reverse stock splits are a common strategy for companies to maintain listing compliance on exchanges like Nasdaq, particularly when their stock price falls below minimum thresholds. This action is often taken to attract institutional investors who may have restrictions on investing in lower-priced stocks.

Comparison to Industry Standards

• Many biotech companies with low share prices have used reverse stock splits to regain compliance with exchange listing requirements.
• For example, companies like Cassava Sciences and Ocugen have also implemented reverse stock splits to maintain their Nasdaq listings.
• The 1-for-10 ratio is a relatively common ratio for reverse stock splits, although some companies have used different ratios depending on their specific circumstances.
• The stated goal of attracting institutional investors is a common motivation for companies undertaking reverse stock splits.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they own, but their percentage ownership will remain the same, except for fractional shares which will be rounded up.
• The reverse stock split is intended to make the company more attractive to institutional investors, potentially increasing demand for the stock.
• The company's employees may be impacted by the company's overall performance and stock price.

Next Steps

• The company will begin trading on a split-adjusted basis on April 2, 2024.
• The company will continue to pursue clinical trials for its drug candidates.
• The company plans to distribute a dividend of shares in HOPE Therapeutics.
• The company expects to file an NDA for ketamine in the second quarter.

Key Dates

Keywords

reverse stock split, NRx Pharmaceuticals, Nasdaq, institutional investors, clinical trials, HTX-100, ketamine, HOPE Therapeutics, shareholder value, NRXP